Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M208995200 on September 19, 2002

J. Biol. Chem., Vol. 277, Issue 48, 45734-45740, November 29, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/48/45734    most recent
M208995200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Berdiev, B. K.
Right arrow Articles by Benos, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berdiev, B. K.
Right arrow Articles by Benos, D. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Protein Kinase C Isoform Antagonism Controls BNaC2 (ASIC1) Function*

Bakhrom K. BerdievDagger , Jiazeng XiaDagger , Biljana JovovDagger , James M. MarkertDagger §, Timothy B. Mapstone, G. Yancey Gillespie§, Catherine M. FullerDagger , James K. BubienDagger , and Dale J. BenosDagger ||

From the Departments of Dagger  Physiology and Biophysics and § Surgery, University of Alabama at Birmingham, Birmingham, Alabama 35294 and the  Department of Neurosurgery, Emory University, Atlanta, Georgia 30322

Received for publication, September 4, 2002, and in revised form, September 19, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We explored the involvement of protein kinase C (PKC) and its isoforms in the regulation of BNaC2. Reverse transcriptase PCR evaluation of PKC isoform expression at the level of mRNA revealed the presence of alpha  and epsilon /epsilon ' in all glioma cell lines analyzed; most, but not all cell lines expressed delta  and zeta . No messages were found for the beta I and beta II isotypes of PKC in the tumor cells. Normal astrocytes expressed beta  but not gamma . The essential features of these results were confirmed at the protein level by Western analysis. This disproportionate pattern of PKC isoform expression in glioma cell lines was further echoed in the functional effects of these PKC isoforms on BNaC2 activity in bilayers. PKC holoenzyme or the combination of PKCbeta I and PKCbeta II isoforms inhibited BNaC2. Neither PKCepsilon nor PKCzeta or their combination had any effect on BNaC2 activity in bilayers. The inhibitory effect of the PKCbeta I and PKCbeta II mixture on BNaC2 activity was abolished by a 5-fold excess of a PKCepsilon and PKCzeta combination. PKC holoenzymes, PKCbeta I, PKCbeta II, PKCdelta , PKCepsilon , and PKCzeta phosphorylated BNaC2 in vitro. In patch clamp experiments, the combination of PKCbeta I and PKCbeta II inhibited the basally activated inward Na+ conductance. The variable expression of the PKC isotypes and their functional antagonism in regulating BNaC2 activity support the idea that the participation of multiple PKC isotypes contributes to the overall activity of BNaC2.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The recent molecular identification of a class of proton-sensitive ion channels (ASIC; acid-sensitive ion channel (1, 2); also called BNC and BNaC; brain Na+ channel (3, 4)) belonging to the degenerin (DEG)/ENaC superfamily of ion channels (5) added a new molecular entity to the already complicated field of nociception. Even though their participation in nociception is controversial, ASICs might underlie some properties of native proton-induced currents (6-8) and could contribute to the function of nociceptive transduction with many other key constituents including nociceptor-specific voltage-gated Na+ channels, ATP-gated channels, and capsaicin receptors (9-13).

The distinguishing feature of this family of ion channels, namely, proton-induced conductance, is exhibited by ASIC1a (14), BNaC2 (4), ASIC1b (15), ASICbeta (16), ASIC2 (or BNC1) (3), BNaC1 (4), MDEG (17), and ASIC3 (DRASIC; 18), hASIC3 (19, 20), and hTNaC1 (21). However, ASIC4 is functionally inactive (22, 23) and may require an association with an accessory protein(s) and/or other subunit(s) of the family, like the splice variant form of ASIC2 (ASIC2b, also called MDEG2) (24) or ASICbeta 2, a splice variant of ASICbeta (25). The multiplicity of current responses to extracellular acid loads in different neurons is consistent with the existence of functionally distinct ASICs in these cells.

The tissue distribution of the ASIC members is not limited to the nervous system but also includes many other tissues such as the lung, testis, and intestine (20, 21, 26, 27). Sensory neuron-specific expression of DRASIC has been reported (18), but Chen et al. (16) have found low level transcripts in superior cervical ganglia, spinal cord, and brain stem. ASICs have been characterized extensively in heterologous expression systems, and besides being implicated in nociception (1, 2), a role in mechanotransduction (28, 29), in the cellular response to an ischemic offense (27, 30, 31), and synaptic plasticity (32, 33), have been proposed.

Despite significant characterization of ASICs, the possible role of second messenger regulation of ASICs has not been reported. Moreover, Bubien et al. (34) reported an amiloride-sensitive Na+ current in malignant brain tumor cells and the presence of BNaC2 message in these cells. Also, human glioma cells show a differential expression of specific PKC1 isoforms compared with normal astroglia (35). With this in mind, we explored the role of PKC and its isoforms in the regulation of BNaC2. We found 1) expression of PKCalpha , PKCepsilon , PKCdelta , and PKCzeta in most cell lines and no expression of PKCbeta in all glioma cell lines compared with normal astrocytes; 2) separately, PKCbeta I and PKCbeta II lacked a channel inhibitory effect, but in combination PKCbeta I and PKCbeta II inhibited channel activity in bilayers, which was comparable with the inhibitory effect of whole PKC; 3) PKCepsilon and PKCzeta individually and in combination did not inhibit BNaC2, but a 5-fold excess of a PKCepsilon and PKCzeta combination abolished the otherwise inhibitory influence of the PKCbeta I and PKCbeta II mixture; 4) whole PKC, PKCbeta I, PKCbeta II, PKCdelta , PKCepsilon , and PKCzeta phosphorylated BNaC2 in vitro; 5) PKCbeta I plus PKCbeta II inhibited inward Na+ currents in human U87-MG glioma cells. Our findings of disproportionate expression of PKC isotypes in glioma cell lines and their antagonism with respect to influencing BNaC2 activity in bilayers suggest that different proportions of PKC isoforms differentially regulate BNaC2 activity. Also, dysregulation of BNaC2 resulting from an altered expression of the PKC isoforms could be responsible for an activated amiloride-sensitive Na+ current seen in glioma cells (34).

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Phospholipids were purchased from Avanti Polar Lipids (Alabaster, AL). PKC, PKC isoforms, and PKC inhibitor peptide 19-31 were purchased from Calbiochem. All other chemicals were reagent grade, and all solutions were made with distilled water and filter-sterilized before use (Sterivex-GS, 0.22 µm filter; Millipore Corp., Bedford, MA).

RT-PCR Detection of PKC Isozyme mRNAs-- Total RNA was isolated from human glioma cells and normal astrocytes using a modification of the method of Chomczynski and Sacchi (36). The integrity of the RNA was verified after electrophoresis through 1% agarose-formaldehyde denaturing gels. One-step RT-PCR was performed to detect PKC isozyme mRNA with a Qiagen OneStep RT-PCR kit. Total reaction mixture was 50 µl, containing 0.2 µg RNA, 0.4 mM of each dNTP, 30 µM of forward and reverse primer, and appropriate OneStep RT-PCR enzyme mix and buffer. RT-PCR was carried out beginning with a single cycle of 50 °C for 30 min (reverse transcription), 95 °C for 15 min (initial PCR activation step), followed by cycles of 94 °C for 1 min, 56 °C for 1 min, and 72 °C for 1 min, for a total of 35 cycles. This was followed by a single cycle of 72 °C for 10 min to facilitate final extension. The primers utilized are listed in Table I.

Primers were synthesized by Invitrogen. All primer sequences were searched in GenBankTM, and no similarities between primers and other human gene sequences were found except for the target gene we intended to amplify. To confirm this, we used full-length cDNAs (ATCC) for human PKC isoform alpha , beta , gamma , epsilon , and zeta  as substrates in PCR reactions with each of the primer pairs. PCR products were analyzed by agarose gel electrophoresis and visualized by ethidium bromide staining. The primers we designed for each isoform generated amplicons only from the appropriate PKC isoform cDNA template and not from the other templates. Authenticity of each product was confirmed by size and digestion with three restriction enzymes, as well as by direct sequencing. Computer analysis of nucleotide and restriction enzyme mapping was done using the Genetics Computer Group Package (37) on a Unix computer and were provided through the University of Alabama at Birmingham Center for AIDS Research. Human lymphocyte RNA preps (volunteer donors) were used as positive controls (data not shown; see Ref. 13).

Western Blot-- The protocol used for Western analyses for different PKC isoforms in glial tumor cell lines was identical to that described earlier (38). The antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA).

In Vitro Phosphorylation by PKC and Its Isoforms-- In vitro phosphorylation by PKC and its isoforms was assayed by measuring the incorporation of [32P] into immunopurified protein (BNaC2) from [gamma -32P]ATP, in a reaction mixture containing 20 mM Tris·HCl, pH 7.5, 10 mM MgCl2, 20 µM ATP, 15-50 kBq of [gamma -32P]ATP, and 1 microunit of PKC or its isoforms. Immunopurification of in vitro translated protein was performed as described previously (38). The incubation was carried out for 3 min at 30 °C, and the phosphorylated proteins were separated by SDS/PAGE and visualized by autoradiography. Where indicated, PKC activity was measured in the presence of 0.5 mM CaCl2 or 1 µM PKC inhibitor (peptide 19-31).

Xenopus Oocyte Membrane Vesicle Preparations-- Standard methods for oocyte isolation, cRNA preparation, and injection were used (39). Oocyte membrane vesicles were prepared as described (39, 40).

Planar Lipid Bilayers-- Oocyte membrane vesicles were fused with planar lipid bilayers made of a 2:1 (w/w) diphytanoyl-phosphatidyl-ethanolamine/diphytanoyl-phosphatidylserine solution in n-octane (final lipid concentration 25 mg/ml). Bilayers were bathed with symmetrical 100 mM NaCl, 10 mM MOPS-Tris, 100 µM EGTA, 50 nM [Ca2+]free, pH 7.4. The Bound-and-Determined computer program was used to calculate the level of free [Ca2+] (41). Phosphorylation mixture contained 10 ng/ml of PKC or its isoforms, 5 µM diacylglycerol, 100 µM Mg-ATP. To verify the orientation of BNaC2 and its block by amiloride, at the end of each experiment 5 µM amiloride was added to the presumptive extracellular side of the channel. Single channel currents were measured using a conventional current-to-voltage converter with a 10 gigaohm feedback resistor (Eltec, Daytona Beach, FL) as described previously (42). Single channel analyses were performed using pCLAMP 5.6 software (Axon Instruments, Burlingame, CA) on current records low pass-filtered at 300 Hz through an 8-pole Bessel filter (902 LPF; Frequency Devices, Haverhill, MA) prior to acquisition using a Digidata 1200 interface (Axon Instruments, Burlingame, CA).

Whole-cell Patch Clamp-- Whole-cell patch clamp experiments were performed on cultured human U87-MG glioma cells as described previously (34). PKC isoforms were included in the pipette solution at a final concentration of 5 ng/ml.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

RT-PCR and Western Blot Detection of PKC Isozymes-- RT-PCR using specific primer pairs for PKCalpha , PKCbeta , PKCdelta , PKCepsilon , PKCgamma , and PKCzeta (Table I) was performed on total RNA isolated from SK-MG1 glioma cells (Fig. 1A, top). A similar analysis was carried out for primary cultures of human astrocytes, three first passage cultures of glioblastoma multiform (GBM) tumor resections (PT1, PT2, and PT3) and ten established cell lines, nine of which were originally derived from GBMs and one (D32GS) from a gliosarcoma (Fig. 1A). These experiments revealed that PKCbeta mRNA was expressed by normal astrocytes but not by any of the tumor cells. The astrocytes expressed all of the PKC isoforms examined, except for PKCgamma . Only PKCalpha and PKCepsilon /epsilon ' were detected in all of the gliomas. Likewise, PKCdelta mRNA was expressed in all samples except D32GS. There was more variability in expression of PKCgamma and PKCzeta . These results demonstrated that PKCalpha , PKCepsilon /epsilon ', and PKCdelta were expressed reliably in all of the GBM glioma cell lines examined and that PKCbeta I and PKCbeta II were not expressed at all (the primer pairs used for the detection of PKCbeta spanned the common region of PKCbeta I and PKCbeta II). Western blot analysis was also performed to examine protein expression of PKCbeta I, PKCepsilon /epsilon ', and PKCzeta in the astrocytes and SK-MG1 and U87-MG cells (Fig. 1B). Similar to the results presented in Fig. 1A, only astrocytes expressed PKCbeta I, all three cell types expressed PKCepsilon /epsilon ', and the astrocytes and SK-MG1, but not U87-MG, expressed PKCzeta .

                              
View this table:
[in this window]
[in a new window]
 
Table I
Primers for reverse transcriptase polymerase chain reaction (RT-PCR)


View larger version (65K):
[in this window]
[in a new window]
  		Fig. 1.   A, RT-PCR using oligonucleotide primers specific for PKC were used to detect unique mRNA transcripts. Surveys were performed using total RNA from human glioma cell lines. Top panel, PKC isoforms analysis in normal human astrocytes and SK-MG1 cells. mRNA for PKC isoforms alpha , beta , delta , epsilon /epsilon ', gamma , and zeta  in human astrocytes, three primary cultures obtained from GBM brain tumor resections (PTI, PT2, PT3), nine continuous cell lines originating from GBMs, and one gliosarcoma (D32GS) are shown. Bottom panels, discrete mRNA were detected in the majority of glioma cell lines for PKC isoforms alpha , delta , epsilon , and zeta  but not PKCbeta or PKCgamma . Control lanes (run in the absence of added cDNA) were all negative and were omitted for clarity. B, Western blot analysis of human astrocytes and SK-MG1 and U87-MG glioma cell lines for PKCbeta I, PKC epsilon /epsilon ', and PKC zeta .

Effects of PKC and Its Isoforms on BNaC2 in Bilayers-- BNaC2 incorporated into planar lipid bilayers forms a functional amiloride-sensitive Na+ channel with a very low probability of being in an open state (PO ~0.08) (43). However, buffering [Ca2+]free in the bilayer bathing solution to <100 nM significantly increases PO and thus provides the opportunity to investigate the effects of PKC and its isoforms on a wild-type active channel. Addition of the phosphorylation mixture (with holoenzyme PKC) to the bilayer bathing solution decreased BNaC2 PO from 0.89 ± 0.09 to 0.45 ± 0.06 without any effect on single channel conductance (Fig. 2A). We next tested the hypothesis that specific PKC isoforms could affect BNaC2 activity in different ways. The rationale for this set of experiments was the following. First, PKC is a large family of related proteins with at least 11 isotypes, each with a distinctive primary structure, expression pattern, and subcellular localization (44). Second, several groups (35, 45) have shown that PKCepsilon /epsilon ' and PKCzeta are overexpressed in many glial tumor cell lines, whereas PKCbeta is reduced or even absent compared with normal human astrocytes (Fig. 1A). Third, amiloride-sensitive Na+ currents were observed in primary cultures of freshly resected tumors and established glioma cell lines (34) along with BNaC mRNA. We began by examining PKCbeta I and PKCbeta II effects on BNaC2 activity in bilayers. When added alone, neither PKCbeta I nor PKCbeta II had any effect on BNaC2 activity (Table II), but their combination significantly decreased BNaC2 PO from 0.91 ± 0.08 to 0.48 ± 0.06; no changes in single conductance were observed (Fig. 2B). This inhibition of BNaC2 activity by the PKCbeta I and PKCbeta II combination was equivalent to that of whole PKC. These results support the hypothesis that PKCbeta I and PKCbeta II are essential, at least in planar lipid bilayers, for the inhibitory effect of PKC on BNaC2 activity. Because of the reported up-regulated levels of PKCepsilon and PKCzeta isotypes, and the expectation that these isoforms could have their own effects on BNaC2 activity, we explored the effect of PKCepsilon and PKCzeta on BNaC2 activity. We found that PKCepsilon and PKCzeta added alone or in combination, did not have any effect on BNaC2 activity (Table II). This outcome prompted us to imitate the differential levels of PKC isoform expression in gliomas in our bilayer experiments. A 5-fold excess of PKCepsilon and PKCzeta relative to PKCbeta I and PKCbeta II was added to the bilayer bathing solution following incorporation of BNaC2. This maneuver abolished the otherwise inhibitory effect of the PKCbeta I and PKCbeta II combination on BNaC2 activity in bilayers (Fig. 2C). We did not observe this effect with a 1:1 ratio of isoforms (Table II). Also, a 5-fold excess of PKCdelta or its combination with PKCepsilon or PKCzeta neither affected BNaC2 activity nor interfered with the inhibitory influence of the PKCbeta I and PKCbeta II combination on BNaC2 activity (Table II).


View larger version (31K):
[in this window]
[in a new window]
  		Fig. 2.   Inhibitory effect of PKC on BNaC2 incorporated into planar lipid bilayer. A, bilayers were bathed with symmetrical 100 mM NaCl, 10 mM MOPS-Tris, 100 µM EGTA, 50 nM [Ca2+]free, pH 7.4. Holding potential was +100 mV referred to the virtually grounded trans-chamber. Dotted lines indicate zero current. Phosphorylation mixture (10 ng/ml of PKC, 5 µM diacylglycerol, 100 µM Mg-ATP) was added to the presumptive intracellular side of the channel. Records shown were filtered at 100 Hz with an 8-pole Bessel filter prior to acquisition at 1 ms per point using pCLAMP software (Axon Instruments, Burlingame, CA). Traces shown are representative of at least five experiments. B, inhibitory effect of PKCbeta I and PKCbeta II combination on BNaC2 incorporated into planar lipid bilayer. Recording and acquisition conditions were the same as for A. Phosphorylation mixture contained, instead of whole PKC, a combination of PKCbeta I (5 ng/ml) and PKCbeta II (5 ng/ml). Traces shown are representative of at least five experiments. C, lack of inhibitory effect of PKCbeta II and PKCbeta II combination on BNaC2 incorporated into planar lipid bilayer in the presence of 5-fold excess of PKCepsilon and PKCzeta combination. Recording and acquisition conditions were the same as for A. Phosphorylation mixture contained, instead of whole PKC, a combination of PKCepsilon (25 ng/ml) and PKCzeta (25 ng/ml). Traces shown are representative of at least five experiments.

                              
View this table:
[in this window]
[in a new window]
 
Table II
The effect of phosphorylation by PKC and its isoforms on properties of BNaC2 in planar lipid bilayers
G, single channel conductance; Po, the open probability of the channel; *, in the presence of 0.983 µM [Ca2+]free; **, in the presence of 2.24 µM [Ca2+]free. Bilayers were bathed with symmetrical 100 mM NaCl, 10 mM MOPS-Tris, 100 µM EGTA, 50 nM [Ca2+]free, pH 7.4. Phosphorylation mixture contained 10 ng/ml PKC or its isoforms, 5 µM diacyl glycerol, 100 µM Mg-ATP. At higher Ca2+ concentrations (0.983 and 2.24 µM), PKCbeta I and PKCbeta II also inhibited BNaC2 channel activity, and this inhibition was in addition to the inhibitory effect of Ca2+ itself on the channel.

In Vitro Phosphorylation of BNaC2 by PKC and Its Isoforms-- Because of the functional effects of PKC and its isoforms on BNaC2 activity in planar bilayers, we hypothesized that BNaC2 should be a substrate for phosphorylation by this kinase and its isoforms. As illustrated in Fig. 3A, BNaC2 can indeed be specifically phosphorylated by PKC (lanes 1 and 2). Elimination of BNaC2 or inclusion of a PKC peptide inhibitor to the reaction mixture prevented phosphorylation of BNaC2 (lanes 3 and 4, respectively). Similarly, PKC isoforms (beta I, beta II, delta , epsilon , and zeta ) phosphorylated BNaC2 (Fig. 3B). Elimination of BNaC2 protein from the reaction mixture prevented BNaC2 phosphorylation (data not shown).


View larger version (46K):
[in this window]
[in a new window]
  		Fig. 3.   Autoradiograph of PKC and its isoforms phosphorylated immunopurified BNaC2. A, BNaC2 was in vitro translated and immunopurified using anti-BNaC2 antibodies. Phosphorylation reactions consisted of 5-10 ng of immunopurified protein, 30 µl of 20 mM Tris-HCl at pH 7.5, 10 mM MgCl2, 20 µM ATP, 15-50 kBq of [gamma -32P]ATP, and 1 microunit of PKC. Reaction was allowed to proceed for 3 min at 30 °C and terminated by addition of 30 µl of 2× SDS sample buffer. Lane 1, all reaction components + 0.5 mM CaCl2; lane 2, all reaction components; lane 3, all reaction components except BNaC2 protein; lane 4, all reaction components + 1 µM PKC inhibitor (peptide 19-31). B, in vitro phosphorylation of BNaC2 by PKC isoforms. The conditions were the same as in A except the phosphorylation reaction contained PKC isoforms instead of whole PKC. Lanes 1-5 correspond to PKCbeta I, PKCbeta II, PKCdelta , PKCepsilon , and PKCzeta , respectively.

The Effects of the PKC Isoform on Inward Na+ Currents in U87-MG Glioma Cells-- Whole-cell patch clamp experiments were performed on cultured human U87-MG glioma cells to test the hypothesis that PKCbeta I + PKCbeta II can inhibit the constitutively activated inward Na+ currents seen in these cells. As a prelude, Fig. 4 presents representative whole-cell patch clamp records from a U87-MG cell before and after treatment with amiloride. Amiloride effectively blocked inward currents. Fig. 5 represents the patch clamp results of the PKC experiments. Inclusion of 5 ng/ml PKCbeta II in the pipette solution had no effect on the inward currents (middle panel). In contrast, PKCbeta I + PKCbeta II abolished the inward currents (right panel). As an additional control, PKCzeta also was without effect (data not shown), consistent with the bilayer findings (Table II).


View larger version (24K):
[in this window]
[in a new window]
  		Fig. 4.   Representative whole-cell patch clamp recordings from a single U87-MG cell: effect of amiloride. Cells were voltage-clamped between -160 and + 100 mV in 20-mV increments from a holding potential of -60 mV. Cells were superfused with RPMI 1640 medium, and the pipette contained the following (in mM): 100 potassium gluconate, 30 KCl, 10 NaCl, 20 HEPES, 0.5 EGTA, 4 ATP, and <10 nM free Ca2+, pH 7.2. After a basal recording (top), amiloride (100 µM) was superfused over the same cell, and another set of voltage-clamp records were obtained (middle). Amiloride effectively abolished inward currents, as seen in the difference curve (bottom). This experiment was repeated four times with identical results.


View larger version (12K):
[in this window]
[in a new window]
  		Fig. 5.   Whole-cell patch clamp recordings from representative U87-MG cells. PKC isoforms were included in the pipette solution at a final concentration of 5 ng/ml. The chord conductance measured between -80 mV, and the reversal potential was (in pS) 5250 ± 1700 (basal), 7318 ± 2316 (PKCbeta II), and 2916 ± 987 (PKCbeta I + beta II); n = 4 for each. The mean conductance value for the PKCbeta I + beta II group was significantly different from the PKCbeta I (p < 0.005), the basal (p < 0.01), or the PKC-zeta (5350 ± 1891 pS; p < 0.01, not shown) groups.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Phosphorylation of BNaC2 by PKC and Its Isoforms-- The effects of PKC phosphorylation on ion channel function can either be stimulatory or inhibitory depending upon the type of ion channel and cell type (46-51). The effects of PKC on amiloride-sensitive Na+ transporting pathways were even more complex and diverse. Activation of PKC greatly diminished Na+ transport in A6 cells (52, 53) and in the LLC-PK1 epithelial cell line (54). PKC also attenuated the activity of purified renal amiloride-sensitive sodium channels (55). Contrary to these outcomes, PKC activation had no effect on Na+ transport in the rat cortical collecting duct (56) and even stimulated sodium transport across frog skin epithelium (57). These discrepancies may arise from reported biphasic effects of PKC on Na+ currents (58) when an initial increase was followed by inhibition of current. These differences may also reflect specific or nonspecific effects of PKC on Na+ transport (59). The inhibitory influence of PKC and its isoforms on BNaC2 activity (Fig. 2) was reminiscent of its effect on cloned ENaC, another degenerin (DEG)/ENaC member, where PKC treatment inhibited single sodium channel activity either in bilayers or following heterologous expression in Xenopus oocytes (60). Our bilayer findings favor the possibility of a direct effect of PKC and its isoforms on BNaC2. This is also supported by the fact that BNaC2 was subject to in vitro phosphorylation by PKC and its individual isoforms (Fig. 3) and by findings of Shimkets et al. (61) showing that beta  and gamma , but not the alpha -ENaC can be phosphorylated in vivo by PKC. Moreover, Stockand et al. (62) showed that PKC inhibition of ENaC may involve differential regulation of subunit levels. PKC activation decreased protein levels of beta  and gamma  but not alpha -ENaC. The conclusion of direct interaction of PKC and BNaC2 does not completely rule out the participation of other components in this interaction. Recent reports (63-65) demonstrated an interaction between members of ASIC family and the PDZ domain-containing proteins, which also interact with PKC. These protein-protein interactions may serve to coalesce the intracellular components necessary for PKC regulation of ASICs. Because of reported PKC isoform regulation of ion transport (66-70), phosphorylation of BNaC2 by different PKC isoforms is of particular interest. First, in in vitro experiments PKCbeta I and PKCbeta II were able to phosphorylate BNaC2 individually, whereas only their combination was able to produce a functional inhibitory effect in bilayers. Moreover, this inhibitory effect was evident in the absence or the presence of an equal ratio of PKCepsilon , and PKCzeta isoforms. An excess of a PKCepsilon and PKCzeta combination, compared with PKCbeta I and PKCbeta II, effectively abolished the inhibitory influence of the latter on BNaC2 activity. Also, addition of PKCbeta I and PKCbeta II to the cytosolic compartment of U87-MG cells effectively abolished inward Na+ currents. These results suggest, at least functionally, that at least two isoforms (beta I and beta II) are required for phosphorylation to observe a functional effect. Second, although PKCepsilon and PKCzeta individually phosphorylated BNaC2 in vitro, they were unable to produce functional effects on BNaC2 in bilayers individually or in combination. Their ability to phosphorylate BNaC2 in vitro was materialized functionally by abolishing the otherwise inhibitory effects of PKCbeta I and PKCbeta II. The nature of molecular events underlying PKCepsilon and PKCzeta effects in preventing BNaC2 phosphorylation by PKCbeta I and PKCbeta II is puzzling, but it is possible that phosphorylation by PKCepsilon and PKCzeta alters the BNaC2 protein in a such way that the phosphorylation site(s) of PKCbeta I and PKCbeta II becomes inaccessible as a result of the involvement of the same or completely different phosphorylation site(s). These observations raise the possibility that the differential expression of PKC isoforms acts as one of many determining factors of the end effect of PKC.

Effects of PKC and Its Isoforms and Glioma Cell Biology-- PKC plays an important role in glioma cell biology. Malignant glioma cells have been reported to express two to three orders of magnitude higher total PKC activity than normal astrocytes (45). Non-isoform-specific PKC inhibitors such as calphostin C and staurosporine (71) can block proliferation of glioma cell lines. Moreover, elevation of PKCalpha levels in U87-MG cells increased invasiveness relative to control cells (72); this effect may be related to matrix metalloproteinases (73). Interestingly, inhibition of PKCalpha and PKCepsilon had no effect on glial cell proliferation, but PKCzeta inhibition blocked proliferation (71). In another study, overexpression of PKCalpha in U87-MG cells increased the proliferation rate (74). Expression of a dominant negative PKCepsilon /epsilon ' mutant in U373-MG astroglial cells also inhibited proliferation (75). Thus, it appears that there are many PKC isoform-specific effects on glial cells, and these effects may extend to an amiloride-sensitive Na+ current in malignant brain tumor cells, attributed to BNaC2 (34). In patch clamp experiments, only a combination of PKCbeta I and PKCbeta II in the pipette solution inhibited the inward currents (Fig. 5). The presence of only PKCbeta II or PKCzeta in the pipette solution had no effect on the inward currents. The same pattern of effects were observed in bilayer experiments: lack of any effect by an individual PKC isoforms, but presence of inhibitory effect of PKCbeta I and PKCbeta II combination. Our RT-PCR results (Fig. 1) demonstrated that only PKCalpha , epsilon /epsilon ', and zeta  were expressed in most all of the glioma cell lines that were examined and that PKCbeta was not expressed at all. Thus, we confirmed that PKCepsilon and PKCzeta are present in gliomas (35, 45) and show for the first time that high grade gliomas do not express PKCbeta , as compared with normal astrocytes.

Our experiments show that total PKC inhibited BNaC2 activity in planar lipid bilayers. Also, we found that an overabundance of specific PKC isoforms, specifically epsilon  and zeta  in the face of reduced PKCbeta , overcame any inhibitory effects of the other PKC isoforms on BNaC2 activity. If expression of BNaC2, and for that matter other members of the ASIC family, is specific to high grade glioma cells, then it is likely that PKC isoform-specific modulation of ASICs contribute to its constitutive activity in glioma cells. This effect may be important in conferring tumor-like characteristics, such as invasiveness and proliferation, to these cells.

    ACKNOWLEDGEMENTS

We gratefully acknowledge Drs. D. P. Corey and J. García-Añoveros (Department of Neurobiology, Harvard Medical School and Howard Hughes Medical Institute) for the kind gift of BNaC DNA.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants DK37206 and CA71933 and the Brain Tumor Foundation for Children.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

|| To whom correspondence should be addressed: University of Alabama at Birmingham, 1918 University Blvd., MCLM 704, Birmingham, AL 35294-0005. Tel.: 205-934-6220; Fax: 205-934-2377; E-mail: benos@physiology.uab.edu.

Published, JBC Papers in Press, September 19, 2002, DOI 10.1074/jbc.M208995200

    ABBREVIATIONS

The abbreviations used are: PKC, protein kinase C; RT, reverse transcriptase; MOPS, 4-morpholinepropanesulfonic acid; GBM, glioblastoma multiform.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Waldmann, R., and Lazdunski, M. (1998) Curr. Opin. Neurobiol. 8, 418-424[CrossRef][Medline] [Order article via Infotrieve]
2. Waldmann, R., Champigny, G., Lingueglia, E., De, Weille, J. R., Heurteaux, C., and Lazdunski, M. (1999) Ann. N. Y. Acad. Sci. 868, 67-76[CrossRef][Medline] [Order article via Infotrieve]
3. Price, M. P., Snyder, P. M., and Welsh, M. J. (1996) J. Biol. Chem. 271, 7879-7882[Abstract/Free Full Text]
4. García-Añoveros, J., Derfler, B., Neville-Golden, J., Hyman, B. T., and Corey, D. P. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 1459-1464[Abstract/Free Full Text]
5. Corey, D. P., and García-Añoveros, J. (1996) Science 273, 323-324[Medline] [Order article via Infotrieve]
6. Krishtal, O. A., and Pidoplichko, V. I. (1980) Neuroscience 12, 2325-2327
7. Krishtal, O. A., and Pidoplichko, V. I. (1981) Neuroscience 24, 243-246
8. Bevan, S., and Yeats, J. (1991) J. Physiol. 433, 145-161[Abstract/Free Full Text]
9. Wood, J. N., and Docherty, R. (1997) Annu. Rev. Physiol. 59, 457-482[CrossRef][Medline] [Order article via Infotrieve]
10. McCleskey, E. W., and Gold, M. S. (1999) Annu. Rev. Physiol. 61, 835-856[CrossRef][Medline] [Order article via Infotrieve]
11. Kress, M., and Zeilhofer, H. U. (1999) Trends Pharmacol. Sci. 20, 112-118[CrossRef][Medline] [Order article via Infotrieve]
12. Caterina, M. J., and Julius, D. (1999) Curr. Opin. Neurobiol. 9, 525-530[CrossRef][Medline] [Order article via Infotrieve]
13. Reeh, P. W., and Kress, M. (2001) Curr. Opin. Pharmacol. 1, 45-51[CrossRef][Medline] [Order article via Infotrieve]
14. Waldmann, R., Champigny, G., Bassilana, F., Heurteaux, C., and Lazdunski, M. (1997) Nature 386, 173-177[CrossRef][Medline] [Order article via Infotrieve]
15. Bässler, E. L., Ngo-Anh, T. J., Geisler, H. S., Ruppersberg, J. P., and Gründer, S. (2001) J. Biol. Chem. 276, 33782-33787[Abstract/Free Full Text]
16. Chen, C. C., England, S., Akopian, A. N., and Wood, J. N. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 10240-10245[Abstract/Free Full Text]
17. Waldmann, R., Champigny, G., Voilley, N., Lauritzen, I., and Lazdunski, M. (1996) J. Biol. Chem. 271, 10433-10436[Abstract/Free Full Text]
18. Waldmann, R., Bassilana, F., de Weille, J., Champigny, G, Heurteaux, C, and Lazdunski, M. (1997) J. Biol. Chem. 272, 20975-20978[Abstract/Free Full Text]
19. de Weille, J. R., Bassilana, F., Lazdunski, M., and Waldmann, R. (1998) FEBS Lett. 433, 257-260[CrossRef][Medline] [Order article via Infotrieve]
20. Babinski, K., Le, K. T., and Seguela, P. (1999) J. Neurochem. 72, 51-57[CrossRef][Medline] [Order article via Infotrieve]
21. Ishibashi, K., and Marumo, F. (1998) Biochem. Biophys. Res. Commun. 245, 589-593[CrossRef][Medline] [Order article via Infotrieve]
22. Akopian, A. N., Chen, C. C., Ding, Y., Cesare, P., and Wood, J. N. (2000) Neuroreport 11, 2217-2222[Medline] [Order article via Infotrieve]
23. Gründer, S., Geissler, H. S., Bässler, E. L., and Ruppersberg, J. P. (2000) Neuroreport 11, 1607-1611[Medline] [Order article via Infotrieve]
24. Lingueglia, E., de Weille, J. R., Bassilana, F., Heurteaux, C., Sakai, H., Waldmann, R., and Lazdunski, M. (1997) J. Biol. Chem. 272, 29778-29783[Abstract/Free Full Text]
25. Ugawa, S., Ueda, T., Takahashi, E., Hirabayashi, Y., Yoneda, T., Komai, S., and Shimada, S. (2001) Neuroreport 12, 2865-2869[CrossRef][Medline] [Order article via Infotrieve]
26. Gunthorpe, M. J., Smith, G. D., Davis, J. B., and Randall, A. D. (2001) Pflugers Arch. 442, 668-674[CrossRef][Medline] [Order article via Infotrieve]
27. Yiangou, Y., Facer, P., Smith, J. A., Sangameswaran, L., Eglen, R., Birch, R., Knowles, C., Williams, N., and Anand, P. (2001) Eur. J. Gastroenterol. Hepatol. 13, 891-896[CrossRef][Medline] [Order article via Infotrieve]
28. Price, M. P., Lewin, G. R., McIlwrath, S. L., Cheng, C., Xie, J., Heppenstall, P. A., Stucky, C. L., Mannsfeldt, A. G., Brennan, T. J., Drummond, H. A., Qiao, J., Benson, C. J., Tarr, D. E., Hrstka, R. F., Yang, B., Williamson, R. A., and Welsh, M. J. (2000) Nature 407, 1007-1011[CrossRef][Medline] [Order article via Infotrieve]
29. García-Añoveros, J., Samad, T. A., Woolf, C. J., and Corey, D. P. (2001) J. Neurosci. 21, 2678-2686[Abstract/Free Full Text]
30. Biagini, G., Babinski, K, Avoli, M, Marcinkiewicz, M., and Seguela, P. (2001) Neurobiol. Dis. 8, 45-58[CrossRef][Medline] [Order article via Infotrieve]
31. Johnson, M. B., Jin, K. L., Minami, M., Chen, D., and Simon, R. P. (2001) J. Cereb. Blood Flow Metab. 21, 734-740[CrossRef][Medline] [Order article via Infotrieve]
32. Wemmie, J. A., Chen, J., Askwith, C. C., Hruska-Hageman, A. M., Price, M. P., Nolan, B. C., Yoder, P. G., Lamani, E., Hoshi, T., Freeman, J. H., and Welsh, M. J. (2002) Neuron. 34, 463-477[CrossRef][Medline] [Order article via Infotrieve]
33. Bianchi, L., and Driscoll, M. (2002) Neuron. 34, 337-340[CrossRef][Medline] [Order article via Infotrieve]
34. Bubien, J. K., Keeton, D. A., Fuller, C. M., Gillespie, G. Y., Reddy, A. T., Mapstone, T. B., and Benos, D. J. (1999) Am. J. Physiol. 276, C1405-C1410[Abstract/Free Full Text]
35. Xiao, H., Goldthwait, D. A., and Mapstone, T. (1994) J. Neurosurg. 81, 734-740[Medline] [Order article via Infotrieve]
36. Chomczynski, P., and Sacchi, N. (1987) Anal. Biochem. 162, 156-159[Medline] [Order article via Infotrieve]
37. Devereux, J., Haeberli, P., and Smithies, O. (1984) Nucleic Acids Res. 12, 387-395[Abstract/Free Full Text]
38. Jovov, B., Tousson, A., Ji, H. L., Keeton, D., Shlyonsky, V., Ripoll, P. J., Fuller, C. M., and Benos, D. J. (1999) J. Biol. Chem. 274, 37845-37854[Abstract/Free Full Text]
39. Awayda, M. S., Ismailov, I. I., Berdiev, B. K., and Benos, D. J. (1995) Am. J. Physiol. 268, C1450-C1459[Abstract/Free Full Text]
40. Perez, G., Lagrutta, A., Adelman, J. P., and Toro, L. (1994) Biophys. J. 66, 1022-1027[Medline] [Order article via Infotrieve]
41. Brooks, S. P., and Storey, K. B. (1992) Anal. Biochem. 201, 119-126[CrossRef][Medline] [Order article via Infotrieve]
42. Ismailov, I. I., Shlyonsky, V. G., Alvarez, O., and Benos, D. J. (1997) J. Physiol. 504, 287-300[Abstract/Free Full Text]
43. Berdiev, B. K., Mapstone, T. B., Markert, J. M., Gillespie, G. Y., Lockhart, J., Fuller, C. M., and Benos, D. J. (2001) J. Biol. Chem. 276, 38755-38761[Abstract/Free Full Text]
44. Dekker, L. V., and Parker, P. J. (1994) Trends Biochem. Sci. 19, 73-77[CrossRef][Medline] [Order article via Infotrieve]
45. Sharif, T. R., and Sharif, M. (1999) Int. J. Oncol. 15, 237-243[Medline] [Order article via Infotrieve]
46. Ismailov, I. I., and Benos, D. J. (1995) Kidney Int. 48, 1167-1179[Medline] [Order article via Infotrieve]
47. Numann, R., Catterall, W. A., and Scheuer, T. (1991) Science 254, 115-118[Abstract/Free Full Text]
48. Wang, W., Sackin, H., and Giebisch, G. (1992) Annu. Rev. Physiol. 54, 81-96[CrossRef][Medline] [Order article via Infotrieve]
49. Lo, C. F., and Numann, R. (1999) Ann. N. Y. Acad. Sci. 868, 431-433[CrossRef][Medline] [Order article via Infotrieve]
50. Stea, A, Soong, T. W., and Snutch, T. P. (1995) Neuron 15, 929-940[CrossRef][Medline] [Order article via Infotrieve]
51. Yang, J., and Tsien, R. W. (1993) Neuron 10, 127-136[CrossRef][Medline] [Order article via Infotrieve]
52. Yanase, M., and Handler, J. S. (1986) Am. J. Physiol. 250, C517-C522[Abstract/Free Full Text]
53. Ling, B. N., and Eaton, D. C. (1989) Am. J. Physiol. 256, F1094-F1103[Abstract/Free Full Text]
54. Mohrmann, M., Cantiello, H. F., and Ausiello, D. A. (1987) Am. J. Physiol. 253, F372-F376[Abstract/Free Full Text]
55. Oh, Y, Smith, P. R., Bradford, A. L., Keeton, D., and Benos, D. J. (1993) Am. J. Physiol. 265, C85-C91[Abstract/Free Full Text]
56. Rouch, A. J., Chen, L., Kudo, L. H., Bell, P. D., Fowler, B. C., Corbitt, B. D., and Schafer, J. A. (1993) Am. J. Physiol. 265, F569-F577[Abstract/Free Full Text]
57. Civan, M. M., Peterson-Yantorno, K., and O'Brien, T. G. (1987) J. Membr. Biol. 97, 193-204[CrossRef][Medline] [Order article via Infotrieve]
58. Els, W. J., Liu, X., and Helman, S. I. (1998) Am. J. Physiol. 275, C120-C129
59. Awayda, M. S. (2000) J. Gen. Physiol. 115, 559-570[Abstract/Free Full Text]
60. Awayda, M. S., Ismailov, I. I., Berdiev, B. K., Fuller, C. M., and Benos, D. J. (1996) J. Gen. Physiol. 108, 49-65[Abstract/Free Full Text]
61. Shimkets, R. A., Lifton, R., and Canessa, C. M. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 3301-3305[Abstract/Free Full Text]
62. Stockand, J. D., Bao, H. F., Schenck, J., Malik, B., Middleton, P., Schlanger, L. E., and Eaton, D. C. (2000) J. Biol. Chem. 275, 25760-25765[Abstract/Free Full Text]
63. Duggan, A., García-Añoveros, J., and Corey, D. P. (2002) J. Biol. Chem. 277, 5203-5208[Abstract/Free Full Text]
64. Hruska-Hageman, A. M., Wemmie, J. A., Price, M. P., and Welsh, M. J. (2002) Biochem. J. 361, 443-450[CrossRef][Medline] [Order article via Infotrieve]
65. Anzai, N., Deval, E., Schaefer, L., Friend, V., Lazdunski, M., and Lingueglia, E. (2002) J. Biol. Chem. 277, 16655-16661[Abstract/Free Full Text]
66. Zhang, Z. H., Johnson, J. A., Chen, L., El-, Sherif, N., Mochly-Rosen, D., and Boutjdir, M. (1997) Circ. Res. 80, 720-729[Abstract/Free Full Text]
67. Hu, K., Mochly-Rosen, D., and Boutjdir, M. (2000) Am. J. Physiol. Heart Circ. Physiol. 279, H2658-H2664[Abstract/Free Full Text]
68. Korchak, H. M., Corkey, B. E., Yaney, G. C., and Kilpatrick, L. E. (2001) Am. J. Physiol. Cell Physiol. 281, C514-C523[Abstract/Free Full Text]
69. Song, J. C., Hanson, C. M., Tsai, V., Farokhzad, O. C., Lotz, M., and Matthews, J. B. (2001) Am. J. Physiol. Cell Physiol. 281, C649-C661[Abstract/Free Full Text]
70. Xiao, G. Q., Qu, Y., Sun, Z. Q., Mochly-Rosen, D., and Boutjdir, M. (2001) Am. J. Physiol. Cell Physiol. 281, C1477-C1486[Abstract/Free Full Text]
71. Donson, A. M., Banerjee, A., Gamboni-Robertson, F., Fleitz, J. M., and Foreman, N. K. (2000) J. Neurooncol. 47, 109-115[CrossRef][Medline] [Order article via Infotrieve]
72. Cho, K. K., Mikkelsen, T., Lee, Y. J., Jiang, F., Chopp, M., and Rosenblum, M. L. (1999) Int. J. Dev. Neurosci. 17, 447-461[CrossRef][Medline] [Order article via Infotrieve]
73. Park, M. J., Park, I. C., Hur, J. H., Rhee, C. H., Choe, T. B., Yi, D. H., Hong, S. I., and Lee, S. H. (2000) Neurosci. Lett. 290, 201-204[CrossRef][Medline] [Order article via Infotrieve]
74. Mandil, R., Ashkenazi, E., Blass, M., Kronfeld, I., Kazimirsky, G., Rosenthal, G., Umansky, F., Lorenzo, P. S., Blumberg, P. M., and Brodie, C. (2001) Cancer Res. 61, 4612-4619[Abstract/Free Full Text]
75. Sharif, T. R., Sasakawa, N., and Sharif, M. (2001) Int. J. Mol. Med. 7, 373-380[Medline] [Order article via Infotrieve]

Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
Y. J. Qadri, B. K. Berdiev, Y. Song, H. L. Lippton, C. M. Fuller, and D. J. Benos
Psalmotoxin-1 Docking to Human Acid-sensing Ion Channel-1
J. Biol. Chem., June 26, 2009; 284(26): 17625 - 17633.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
E. Bashari, Y. J. Qadri, Z.-H. Zhou, N. Kapoor, S. J. Anderson, R. H. Meltzer, C. M. Fuller, and D. J. Benos
Two PKC consensus sites on human acid-sensing ion channel 1b differentially regulate its function
Am J Physiol Cell Physiol, February 1, 2009; 296(2): C372 - C384.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Chai, M. Li, J. Lan, Z.-G. Xiong, J. A. Saugstad, and R. P. Simon
A Kinase-anchoring Protein 150 and Calcineurin Are Involved in Regulation of Acid-sensing Ion Channels ASIC1a and ASIC2a
J. Biol. Chem., August 3, 2007; 282(31): 22668 - 22677.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
J. K. Bubien, H.-L. Ji, G. Y. Gillespie, C. M. Fuller, J. M. Markert, T. B. Mapstone, and D. J. Benos
Cation selectivity and inhibition of malignant glioma Na+ channels by Psalmotoxin 1
Am J Physiol Cell Physiol, November 1, 2004; 287(5): C1282 - C1291.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B. K. Berdiev, J. Xia, L. A. McLean, J. M. Markert, G. Y. Gillespie, T. B. Mapstone, A. P. Naren, B. Jovov, J. K. Bubien, H.-L. Ji, et al.
Acid-sensing Ion Channels in Malignant Gliomas
J. Biol. Chem., April 18, 2003; 278(17): 15023 - 15034.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. S. Leonard, O. Yermolaieva, A. Hruska-Hageman, C. C. Askwith, M. P. Price, J. A. Wemmie, and M. J. Welsh
cAMP-dependent protein kinase phosphorylation of the acid-sensing ion channel-1 regulates its binding to the protein interacting with C-kinase-1
PNAS, February 18, 2003; 100(4): 2029 - 2034.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/48/45734    most recent
M208995200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Berdiev, B. K.
Right arrow Articles by Benos, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berdiev, B. K.
Right arrow Articles by Benos, D. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement